Guidelines for the use of recombinant human erythropoietin.
Barosi
G
G
Clinica Medica 2, IRCCS Policlinico S. Matteo, Pavia, Italy.
Cazzola
M
M
De Vincentiis
A
A
Grossi
A
A
Tura
S
S
D000740:Anemia / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D002986:Clinical Trials as Topic / Q000379:methods; D003362:Cost-Benefit Analysis; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D000090463:Iron Deficiencies; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D013163:Splenomegaly / Q000139:chemically induced
D011994:Recombinant Proteins; D004921:Erythropoietin